The Carlyle Group Acquires Unchained Labs

Unchained Labs Acquires Blacktrace Group from Maven

July 24, 2023

Medical Devices

Unchained Labs, backed by Carlyle-affiliated investment funds and Unchained management, has acquired Blacktrace Group (Blacktrace Holdings) from investor Maven. The acquisition brings Blacktrace’s microfluidics and Particle Works LNP formulation and scale-up technologies into Unchained’s life-science tools portfolio to accelerate capabilities for lipid nanoparticle, gene therapy and vaccine research.

The Carlyle Group and Management Acquire Unison from Abry Partners

June 29, 2020

Software

Global investment firm The Carlyle Group, together with Unison management, has acquired Unison from Abry Partners. Carlyle will partner with Unison’s management to invest in and grow the company’s cloud-based procurement, supply chain and contract management software for U.S. federal agencies and government contractors.

Unchained Labs Acquires NanoView Biosciences

May 4, 2022

Biotechnology

Unchained Labs, a life-sciences tools company based in Pleasanton, California, acquired NanoView Biosciences to add exosome and viral-vector characterization technologies (ExoView and LentiView) to its product portfolio. The acquisition expands Unchained Labs' capabilities for gene therapy and biologics researchers by integrating NanoView's microchip-based interferometry and fluorescence platforms.

The Carlyle Group Acquires Majority Stake in TriNetX

September 21, 2020

Healthcare Services

The Carlyle Group has made a strategic growth investment to acquire a majority stake in TriNetX, a global health research network that provides real-world clinical and claims data and analytics. Carlyle's investment will accelerate TriNetX's development of clinical research capabilities, support global expansion, and fund both organic and inorganic growth opportunities.

Carlyle Acquires Abingworth to Expand Global Healthcare & Life Sciences Investing

August 3, 2022

Healthcare Services

Global investment firm Carlyle has acquired Abingworth, a transatlantic life sciences investment firm with about $2 billion in assets under management, to broaden Carlyle's healthcare franchise and capabilities across venture to buyouts. The deal brings Abingworth's specialized team and clinical co-development expertise into Carlyle and establishes Launch Therapeutics, an operating company to accelerate late-stage clinical development; terms were not disclosed.

Carlyle Acquires Majority Stake in Incubeta

November 16, 2022

Marketing & Advertising

The Carlyle Group, via its Carlyle Europe Technology Partners platform, has agreed to acquire a majority stake in Incubeta, a London-headquartered digital marketing and ad-tech agency. Carlyle will support Incubeta's international growth, investments in proprietary technology and commercial operations, and M&A-led market consolidation; terms were not disclosed.